Trial Profile

A prospectively randomized controlled clinical trial comparing TheraSphere with cisplatin-based TACE (Trans Arterial Chemo Embolization) in the management of advanced stage, unresectable hepatocellular carcinoma (HCC).

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Jan 2016 Biomarkers information updated
11 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
24 Jan 2013 Results from a retrospective analysis of this trial will be presented at an educational symposium at the 2013 Gastrointestinal Cancers Symposium according to a Nordion media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com